PTPRC and neoplasm: In order to comprehensively investigate changes in immune cells within the tumor microenvironment, we conducted scRNA-seq on CD45+ TILs isolated from CT26 tumors across five experimental groups: control, DSP-0509 monotherapy, anti-PD-1 antibody monotherapy, responder to the combination treatment (Combo_R), and non-responder to the combination treatment (Combo_NR) (Supplementary Figure 2).